Mankind Pharma on Tuesday reported that its consolidated net profit increased 29% in the second quarter of fiscal 2025. The company posted a net profit of Rs 658.88 crore in the quarter ended Sept. 30, 2024, in comparison with Rs 473 crore in the year-ago period.
“We are pleased to report steady revenue growth of 13.6% YoY with strong EBITDA margins of 27.7%, driven by recovery in volume, continued outperformance in chronic segment and operating leverage. OTC business has been carved out to a WOS 2 of Mankind Pharma. From Q3, this business has embarked on the journey towards its next phase of growth. Our acquisition of BSV, perfectly aligns with our vision to expand into high entry barrier portfolio with #1 player in the gynaecology segment, leadership in certain critical care products and further enhance our R&D capabilities. Multiple growth levers – resilient base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV. Together, these levers will propel our growth journey ahead,” Rajeev Juneja – Vice Chairman & Managing Director, Mankind Pharma said.
The company’s revenue from Operations at Rs. 3,077 Cr, up by 14% YoY. The domestic revenue at INR 2,796 Cr, up 11% YoY; Exports at INR 281 Cr, up 57% YoY. The pharma major reported EBITDA margin of 27.7% and PAT margin of 21.4%.
In exports, the company reported revenue growth of 57% YoY driven by increase in our base business supported by new launches in last 12-24 months. During the quarter, we have launched 1 new product in US taking the total launched products to 42.
